CRISPR Therapeutics jumps as CASGEVY revenue ramp draws renewed buying after Q1 update
CRSP•CRISPR Therapeutics shares rose after Q1 2026 results highlighted a $43 million CASGEVY commercial contribution and a ramp in treated patients. The move also reflects a rebound from the prior session’s post-earnings dip as investors refocus on the launch trajectory with partner Vertex.
1. What’s moving the stock today (May 6, 2026)
CRISPR Therapeutics (CRSP) is higher today as investors digest the company’s first-quarter 2026 update showing meaningful commercial traction for CASGEVY, including a reported $43 million contribution tied to the launch. The shares are also snapping back after a sharp decline in the prior session, suggesting the market is re-pricing the update more constructively as the initial commercial ramp becomes more visible. (stocktitan.net)
